Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeLuRide-006: EIK1001 plus pembrolizumab versus placebo plus pembrolizumab in first-line advanced melanoma
2024-512659-19-00Phase 3Authorised
- Sponsor
- Eikon Therapeutics
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing EIK1001 + pembrolizumab with Placebo + pembrolizumab (2 arms). Primary endpoints: Objective response, adverse events, and discontinuation due to adverse events (Dose Optimization), Progression-free survival and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
BDB001pembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-512659-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512659-19-00.